Intravenous Tapentadol in Post-Bunionectomy Pain

Pain Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Parallel Group, Multicenter Trial to Evaluate the Efficacy and Safety of Multiple Dose Administration of an Intravenous Formulation of Tapentadol in the Treatment of Acute Pain Following Bunionectomy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01435577
• Other study ID #: 295054
• Status: Completed
• Phase: Phase 2
• Start date: September 2011
• Est. completion date: February 2012

Study information

• Verified date: October 2019
• Source: Grünenthal GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to established the safety and efficacy of multiple dose treatment with tapentadol IV in an adult population with moderate to severe pain following bunionectomy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 177
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Scheduled to undergo primary unilateral first metatarsal bunionectomy

• Female patients must be postmenopausal, surgically sterile, or practicing an effective method of birth control if they are sexually active

• Qualifying pain intensity (within a maximum of 5 hours after the last surgical stitch) and Baseline pain intensity (last pain score measured within 10 minutes before dosing) 5 on an 11-point (0 to 10) pain intensity numerical rating scale (NRS).

Exclusion Criteria:

• History of malignancy within the past 2 years

• Current or history of alcohol or drug abuse.

• Clinically relevant pulmonary, gastrointestinal, endocrine, metabolic, neurological, psychiatric disorders (resulting in disorientation, memory impairment or inability to report accurately

• History of seizure disorder, epilepsy, or any condition that would put the subject at risk of seizures

• Severely impaired renal function

• Moderately or severely impaired hepatic function

• Contraindications, or a history of allergy or hypersensitivity, to tapentadol, ibuprofen, or excipients

• Use of prohibited concomitant medication, or not allowed use of restricted concomitant medication

Related Conditions & MeSH terms

• Bunion
• Pain

Intervention

Drug:
• Tapentadol
30 mg per administration, maximum 12 administrations over 48 hours
• Matching Placebo
Maximum 12 administrations over 48 hours

Locations

Country	Name	City	State
United States	Jean Brown Research	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Grünenthal GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sum of Pain Intensity Differences (SPID 24)	Pain Intensity assessed at predefined time points (at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 hours after first drug administration) over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates "no pain" and a score of ten indicates "pain as bad as you can imagine". Pain Intensity Differences at each predefined time point (calculated as post-baseline NRS values - baseline NRS values) were analyzed. Negative SPID24 values indicate a decrease in pain intensity and positive values indicate an increase in pain intensity since baseline.	Baseline value; up to 24 hours after first study drug administration
Secondary	Mean Pain Intensity Scores at Fixed Time Points	The mean pain intensity at fixed time points in the trial for all participants is listed. The pain intensity was measured using the Pain Intensity (PI). Pain intensity was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine.	Baseline; up to 48 hours
Secondary	Pain Intensity Differences at Fixed Time Points	Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between baseline pain intensity (prior to the first dose) and the pain intensity at the time. A negative number indicates a decrease in pain in the whole treatment group. The greater the negative pain intensity difference value the greater the pain relief in the treatment arm. A score of 0 indicates that there has been no change in pain in a treatment group. A positive value indicates an increase in pain in the treatment group.	Starting at 15 minutes and up to 48 hours after first drug administration
Secondary	Patient Global Impression of Change After 12 Hours of Treatment	In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant verbally rated their impression of overall status with 1 of 7 possible responses (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse).	Baseline value to 12 hours after first study drug administration
Secondary	Patients Global Impression of Change After 24 Hours of Treatment	In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant verbally rated their impression of overall status with 1 of 7 possible responses (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse).	Baseline value to 24 hours after study drug administration
Secondary	Patient Global Impression of Change After 48 Hours of Treatment	In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant verbally rated their impression of overall status with 1 of 7 possible responses (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse).	Baseline value to 48 hours after first study drug administration
Secondary	Sum of Pain Intensity Differences After 60 Minutes	Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 60 minutes was calculated. If the value is negative then the baseline pain intensity was greater than the pain intensity measured after dosing.	Baseline value to 60 minutes after first study drug administration
Secondary	Sum of Pain Intensity Differences After 4 Hours	Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 4 hours was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).	Baseline value to 4 hours after first study drug intake
Secondary	Sum of Pain Intensity Differences After 8 Hours	Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 8 hours was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).	Baseline value to 8 hours after first study drug administration
Secondary	Sum of Pain Intensity Differences After 12 Hours	Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 12 hours was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).	Baseline value to 12 hours after first study drug administration
Secondary	Sum of Pain Intensity Differences After 48 Hours	Pain Intensity (PI) was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine. Pain Intensity Difference (PID) was the difference between the PI after fixed times after first dose and the baseline PI (prior to the first dose). The Sum of Pain Intensity Differences over 60 minutes was calculated. If the values are negative (then the baseline pain intensity was greater than the pain intensity measured after dosing).	Baseline value to 48 hours after first study drug administration
Secondary	Number of Participants With 30% Response After 12 Hours, Based on Pain Intensity Scores	Individual participant response. Number of participants that reported a 30% or more reduction in pain intensity from the administration of the first dose to 12 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 30% from their baseline value.	Baseline value to 12 hours after first study drug administration
Secondary	Number of Participants With 30% Response After 24 Hours, Based on Pain Intensity Scores	Individual participant response. Number of participants that reported a 30% or more reduction in pain intensity from the administration of the first dose to 24 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 30% from their baseline value.	Baseline value to 24 hours after first study drug administration
Secondary	Number of Participants With 30% Response After 48 Hours, Based on Pain Intensity Scores	Individual participants response. Number of participants that reported a 30% or more reduction in pain intensity from the administration of the first dose to 48 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 30% from their baseline value.	Baseline value to 48 hours after first study drug administration
Secondary	Number of Participants With 50% Response After 12 Hours, Based on Pain Intensity Scores	Individual participant response. Number of participants that reported a 50% or more reduction in pain intensity from the administration of the first dose to 12 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 50% from their baseline value.	Baseline value to 12 hours after first study drug administration
Secondary	Number of Participants With 50% Response After 24 Hours, Based on Pain Intensity Scores	Individual participant response. Number of participants that reported a 50% or more reduction in pain intensity from the administration of the first dose to 24 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 50% from their baseline value.	Baseline value to 24 hours after first study drug administration
Secondary	Number of Participants With 50% Response After 48 Hours, Based on Pain Intensity Scores	Individual participant response. Number of participants that reported a 50% or more reduction in pain intensity from the administration of the first dose to 48 hours after the first study drug administration are counted as having a response if their pain intensity decreased by 50% from their baseline value.	Baseline value to 48 hours after first study drug administration
Secondary	Time to First Rescue Medication	The median time to first rescue medication intake (600 mg ibuprofen) in hours.	up to 48 hours
Secondary	Time to Perceptible Pain Relief	When the participant began to feel any pain-relieving effect after the administration of the first dose they were requested to stop the first stopwatch. The time was noted. This measured when the participant first felt any difference in the pain.	up to 48 hours
Secondary	Time to Meaningful Pain Relief	The participant was instructed to stop the stopwatch when they had meaningful pain relief. That is, when the pain relief made a real difference, after the first drug administration.	up to 48 hours
Secondary	Pharmacokinetic Concentrations of Tapentadol	Tapentadol concentrations were measured in participants in the tapentadol treatment arm. Serum was analyzed by means of liquid chromatography coupled to tandem mass spectrometry with a lower limit of quantification (LLOQ) at 0.2 ng/mL.	15 minutes to 20 hours after first drug administration
Secondary	Pharmacokinetic Concentrations of Tapentadol-O-glucuronide	Tapentadol-O-glucuronide is the metabolite of tapentadol. Metabolites are sometimes referred to as "breakdown products". The body alters the administered medication to a metabolite so that can be more easily or quickly removed from the body. Tapentadol-O-glucuronide concentrations were measured in participants in the tapentadol treatment arm. Serum was analyzed by means of liquid chromatography coupled to tandem mass spectrometry with a lower limit of quantification (LLOQ) at 0.2 ng/mL.	15 minutes to 20 hours after first drug administration
Secondary	Mean Pain Intensity Scores at Relative Time- Tapentadol Randomized Participants	The pain intensity at the relative time points are the pain intensity before and one hour after study drug administration. The pain intensity was measured using the Pain Intensity (PI). Pain intensity was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine.	Baseline; for the first 6 administrations
Secondary	Mean Pain Intensity Scores at Relative Time - Matching Placebo Randomized Participants	The pain intensity at the relative time points are the pain intensity before and one hour after study drug administration. The pain intensity was measured using the Pain Intensity (PI). Pain intensity was assessed on 11-point numerical rating scale from 0 = no pain to 10 = pain as bad as you can imagine.	Baseline; for the first 6 administrations